UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

BMC Nephrology

Guidelines

James O. Burton¹  David Webb²  Mohsen El Kossi³  Matt Holloway⁴  Sunil Bhandari⁵  Andrew H. Frankel⁶  Apexa Kuverji⁷  Eirini Lioudaki⁸  Chris Carvalho⁹  Patrick Holmes^1,10  Alex Riding^1,11  Natalie Staplin^1,12  Alistair J. Roddick^1,13  William G. Herrington^1,13  Michael A. Watson^1,14  Angela Watt^1,14  Alexa Wonnacott^1,15  Donald Fraser^1,15 

[1] Department of Cardiovascular Sciences, University of Leicester, Leicester, UK;Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK;Doncaster Royal Infirmary, Doncaster, UK;East Kent Hospitals University NHS Foundation Trust, Canterbury, UK;Hull University Teaching Hospitals NHS Trust and Hull York Medical School, Hull, UK;Imperial College Healthcare NHS Trust, London, UK;John Walls Renal Unit, Glenfield Hospital, Leicester, UK;Kings College Hospital NHS Trust, London, UK;North East London Integrated Care Board, London, UK;Clinical Effectiveness Group, Queen Mary University of London, London, UK;Primary Care Diabetes Society, Darlington, UK;Royal Free London NHS Foundation Trust, London, UK;The Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK;The Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK;Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;UKKA Patient Representative, Bristol, UK;Wales Kidney Research Unit, Cardiff University, Cardiff, UK;

关键词: Guideline;    Chronic kidney disease;    Acute kidney injury;    Gliflozin;   

DOI  :  10.1186/s12882-023-03339-3

 received in 2023-04-25, accepted in 2023-09-19,  发布年份 2023

来源: Springer

【 摘 要 】

Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full “lay” summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 3

Fig. 12

12936_2017_2014_Article_IEq61.gif

Fig. 4